Clinical trial
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast…
NCT00241046 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00241046 |
|---|---|
| Title | Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment |
| Official title | Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 13 |
| Start date | Apr 1, 2002 |
| Primary completion | Mar 1, 2005 |
| First posted | Oct 18, 2005 |
| Last update posted | Apr 19, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: